AdvanTIG-205

AdvanTIG-205: A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Previously Untreated Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Study Link: https://clinicaltrials.gov/ct2/show/NCT05014815

Atridia SHR-A1811-I-101

A Phase 1 Multi-Country, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subjects

Study Link: https://clinicaltrials.gov/ct2/show/NCT04446260

InventisBio_D1553-101

A Phase 1/2, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects With Advanced or Metastatic Solid Tumors With KRasG12C Mutation

Study Link: https://clinicaltrials.gov/ct2/show/NCT04585035

ARX788-1711

A Phase 1, Multicenter, Dose-escalation and Expansion Study of ARX788 as Monotherapy in Advanced Solid Tumors with HER2-expression or mutation

Study Link: https://clinicaltrials.gov/ct2/show/NCT03255070

EpimAb EMB02X101 Phase I

A Phase I/II Trial of EMB-02, a Bi-specific Antibody Against PD-1 and LAG-3, in Patients with Advanced Solid Tumors

Study Link: https://clinicaltrials.gov/ct2/show/NCT04618393

Epimab EMB09X101

A First-in-human, Phase I Trial of EMB-09, a Bispecific Antibody Targeting PD-L1 and OX-40 in Patients with Advanced or metastatic Solid Tumors

Study Link: https://clinicaltrials.gov/ct2/show/NCT05263180

Bayer 21140

A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus placebo plus ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC)

Study Link: https://clinicaltrials.gov/ct2/show/NCT04736199

CA2097DX CheckMate 7DX

A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer

Study Link: https://clinicaltrials.gov/ct2/show/NCT04100018

ENZAMET

Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer

Study Link: https://clinicaltrials.gov/ct2/show/NCT02446405

Daiichi Sankyo DS8201-A-U302

A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

Study Link: https://clinicaltrials.gov/ct2/show/NCT03529110